Benefits of two locally delivered agents on cytokine levels in smokers with chronic periodontitis.
Not Applicable
- Conditions
- Health Condition 1: K053- Chronic periodontitisHealth Condition 2: Z779- Other contact with and (suspected)exposures hazardous to health
- Registration Number
- CTRI/2021/05/033333
- Lead Sponsor
- PANINEEYA INSTITUTE OF DENTAL SCIENCES AND RESEARCH CENTRE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with history of smoking
Current smokers - patients who smoke more than 5 cigarettes per day per the past one month
Former smokers - patients who used to smoke more than 5 cigarettes per day and have quit the habit for the past one month
Patients with chronic periodontitis with 20 teeth remaining and probing pocket depth more than 5mm in one or more sites
Exclusion Criteria
Pregnant and lactating women
Systemically compromised patients
use of medicines or antibiotics 3 months before the enrollment
History of periodontal treatment within 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Estimation of interleukin 1 beta levels in gingival crevicular fluid <br/ ><br>Timepoint: Baseline and 6 weeks after scaling and root planing <br/ ><br>
- Secondary Outcome Measures
Name Time Method Estimation of clinical parameters like plaque index and probing pocket depth will be assessed with williams probeTimepoint: Baseline , 8 weeks and 12 weeks after scaling and root planing;Estimation of interleukin 1 beta by ELISATimepoint: At baseline and 6 weeks after scaling and root planing